1. Home
  2. VRTX vs LOW Comparison

VRTX vs LOW Comparison

Compare VRTX & LOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • LOW
  • Stock Information
  • Founded
  • VRTX 1989
  • LOW 1946
  • Country
  • VRTX United States
  • LOW United States
  • Employees
  • VRTX N/A
  • LOW N/A
  • Industry
  • VRTX EDP Services
  • LOW RETAIL: Building Materials
  • Sector
  • VRTX Technology
  • LOW Consumer Discretionary
  • Exchange
  • VRTX Nasdaq
  • LOW Nasdaq
  • Market Cap
  • VRTX 128.5B
  • LOW 150.3B
  • IPO Year
  • VRTX 1991
  • LOW N/A
  • Fundamental
  • Price
  • VRTX $467.01
  • LOW $271.78
  • Analyst Decision
  • VRTX Buy
  • LOW Buy
  • Analyst Count
  • VRTX 29
  • LOW 25
  • Target Price
  • VRTX $513.58
  • LOW $272.84
  • AVG Volume (30 Days)
  • VRTX 1.2M
  • LOW 2.3M
  • Earning Date
  • VRTX 11-04-2024
  • LOW 11-19-2024
  • Dividend Yield
  • VRTX N/A
  • LOW 1.70%
  • EPS Growth
  • VRTX N/A
  • LOW 20.25
  • EPS
  • VRTX N/A
  • LOW 12.06
  • Revenue
  • VRTX $10,625,800,000.00
  • LOW $84,023,000,000.00
  • Revenue This Year
  • VRTX $12.20
  • LOW N/A
  • Revenue Next Year
  • VRTX $8.31
  • LOW $1.86
  • P/E Ratio
  • VRTX N/A
  • LOW $22.54
  • Revenue Growth
  • VRTX 10.06
  • LOW N/A
  • 52 Week Low
  • VRTX $346.29
  • LOW $196.23
  • 52 Week High
  • VRTX $519.88
  • LOW $287.01
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 42.88
  • LOW 53.95
  • Support Level
  • VRTX $489.02
  • LOW $269.44
  • Resistance Level
  • VRTX $519.88
  • LOW $276.77
  • Average True Range (ATR)
  • VRTX 14.86
  • LOW 4.94
  • MACD
  • VRTX -2.67
  • LOW 0.24
  • Stochastic Oscillator
  • VRTX 14.49
  • LOW 74.44

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About LOW Lowe's Companies Inc.

Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.

Share on Social Networks: